

# Adverse Effects of Low-Dose Methotrexate

Annals of Internal Medicine

172, 369

DOI: 10.7326/m19-3369

Citation Report

#	ARTICLE	IF	CITATIONS
1	Rheumatoid arthritis-related lung disease detected on clinical chest computed tomography imaging: Prevalence, risk factors, and impact on mortality. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 1216-1225.	1.6	18
2	Adverse Effects of Low-Dose Methotrexate in a Randomized Double-Blind Placebo-Controlled Trial: Adjudicated Hematologic and Skin Cancer Outcomes in the Cardiovascular Inflammation Reduction Trial. <i>ACR Open Rheumatology</i> , 2020, 2, 697-704.	0.9	18
4	A randomised clinical trial of methotrexate points to possible efficacy and adaptive immune dysfunction in psychosis. <i>Translational Psychiatry</i> , 2020, 10, 415.	2.4	30
5	Adverse Effects of Low-Dose Methotrexate. <i>Annals of Internal Medicine</i> , 2020, 173, 166-167.	2.0	5
6	A Call to Systematically Monitor for Adverse Events in Users of Low-Dose Methotrexate Therapy. <i>Annals of Internal Medicine</i> , 2020, 172, 425.	2.0	3
7	Comment on: Cytopenias among patients with rheumatic diseases using methotrexate: a meta-analysis of randomized controlled clinical trials: reply. <i>Rheumatology</i> , 2020, 59, e76-e76.	0.9	0
8	“Should we stop or continue conventional synthetic (including glucocorticoids) and targeted DMARDs before surgery in patients with inflammatory rheumatic diseases?” <i>RMD Open</i> , 2020, 6, e001214.	1.8	15
9	Pulmonary Adverse Events in Patients Receiving Low-Dose Methotrexate in the Randomized, Double-Blind, Placebo-Controlled Cardiovascular Inflammation Reduction Trial. <i>Arthritis and Rheumatology</i> , 2020, 72, 2065-2071.	2.9	26
10	The Impact of Obesity on Disease Activity and Treatment Response in Rheumatoid Arthritis. <i>Current Rheumatology Reports</i> , 2020, 22, 56.	2.1	23
11	Acute respiratory viral adverse events during use of antirheumatic disease therapies: A scoping review. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 1191-1201.	1.6	19
12	Rheumatoid Arthritis-Associated Interstitial Lung Disease: Current Update on Prevalence, Risk Factors, and Pharmacologic Treatment. <i>Current Treatment Options in Rheumatology</i> , 2020, 6, 337-353.	0.6	35
13	Aliskiren, tadalafil, and cinnamaldehyde alleviate joint destruction biomarkers; MMP-3 and RANKL; in complete Freund's adjuvant arthritis model: Downregulation of IL-6/JAK2/STAT3 signaling pathway. <i>Saudi Pharmaceutical Journal</i> , 2020, 28, 1101-1111.	1.2	16
14	Smart battles: immunosuppression versus immunomodulation in the inflammatory RMDs. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 991-993.	0.5	17
15	Methotrexate: what are the true risks of treatment?. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1267-1268.	0.5	4
16	Navigating immunosuppression in a pandemic: A guide for the dermatologist from the COVID Task Force of the Medical Dermatology Society and Society of Dermatology Hospitalists. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1150-1159.	0.6	27
18	Poisoning related to therapeutic error in prolonged low-dose methotrexate treatment. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 2385-2391.	1.1	2
19	Inferences About Drug Safety in Phase III Trials in Oncology: Examples From Advanced Prostate Cancer. <i>Journal of the National Cancer Institute</i> , 2021, 113, 553-561.	3.0	12
20	Metotrexato en la neumatía intersticial asociada a la artritis reumatoide. <i>Reumatología Clínica</i> , 2021, , .	0.2	0

#	ARTICLE	IF	CITATIONS
21	Risk for infections with glucocorticoids and DMARDs in patients with rheumatoid arthritis. <i>RMD Open</i> , 2021, 7, e001235.	1.8	20
22	Influence of keratolytics on cutaneous pharmacokinetics of glucocorticoids. <i>JDDG - Journal of the German Society of Dermatology</i> , 2021, 19, 554-561.	0.4	3
23	Are long-chain methotrexate polyglutamate levels the reason for LD-MTX related adverse events in inflammatory arthritis?. <i>Expert Review of Clinical Pharmacology</i> , 2021, 14, 285-287.	1.3	0
24	Potential contributors to low dose methotrexate toxicity in a patient with rheumatoid arthritis and pernicious anemia: case report. <i>BMC Rheumatology</i> , 2021, 5, 5.	0.6	6
25	The Key Comorbidities in Patients with Rheumatoid Arthritis: A Narrative Review. <i>Journal of Clinical Medicine</i> , 2021, 10, 509.	1.0	44
26	Respuesta a la carta al editor: Metotrexato en la neumopatía intersticial asociada a la artritis reumatoide. <i>Reumatología Clínica</i> , 2021, , .	0.2	0
27	Delay of endoscopic submucosal dissection-induced gastric ulcer healing by methotrexate. <i>Clinical Journal of Gastroenterology</i> , 2021, 14, 754-758.	0.4	2
28	What is the incidence of methotrexate or leflunomide discontinuation related to cytopenia, liver enzyme elevation or kidney function decline?. <i>Rheumatology</i> , 2021, 60, 5785-5794.	0.9	17
29	TNF in the era of immune checkpoint inhibitors: friend or foe?. <i>Nature Reviews Rheumatology</i> , 2021, 17, 213-223.	3.5	77
31	Gastrointestinal Adverse Drug Reaction Profile of Etanercept: Real-world Data From Patients and Healthcare Professionals. <i>Journal of Rheumatology</i> , 2021, 48, 1388-1394.	1.0	2
32	Effect of Half-Dose vs Stable-Dose Conventional Synthetic Disease-Modifying Antirheumatic Drugs on Disease Flares in Patients With Rheumatoid Arthritis in Remission. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 1755.	3.8	17
33	Therapeutic Prospects of Cannabinoids in the Immunomodulation of Prevalent Autoimmune Diseases. <i>Cannabis and Cannabinoid Research</i> , 2021, 6, 196-210.	1.5	21
34	Low-dose methotrexate in dermatology: the utility of serological monitoring in a real-world cohort. <i>Journal of Dermatological Treatment</i> , 2021, , 1-7.	1.1	0
35	Adverse Effects of Medications on Micronutrient Status: From Evidence to Guidelines. <i>Annual Review of Nutrition</i> , 2021, 41, 411-431.	4.3	1
36	Reintroduction of immunosuppressive medications in pediatric rheumatology patients with histoplasmosis: a case series. <i>Pediatric Rheumatology</i> , 2021, 19, 84.	0.9	4
38	Answer to the Letter to the Editor: Methotrexate in interstitial lung disease associated with rheumatoid arthritis. <i>Reumatología Clínica (English Edition)</i> , 2021, , .	0.2	0
39	Efficacy of berberine in treatment of rheumatoid arthritis: From multiple targets to therapeutic potential. <i>Pharmacological Research</i> , 2021, 169, 105667.	3.1	28
40	Preclinical evaluation of methotrexate-loaded polyelectrolyte complexes and thermosensitive hydrogels as treatment for rheumatoid arthritis. <i>European Journal of Pharmaceutical Sciences</i> , 2021, 163, 105856.	1.9	8

#	ARTICLE	IF	CITATIONS
41	Medications for Multiple Sclerosis and Risk of Malignancy: What Next?. <i>Neurotherapeutics</i> , 2021, 18, 1650-1653.	2.1	5
42	Integrated Metabolomics and Transcriptomics Analyses Reveal Histidine Metabolism Plays an Important Role in Imiquimod-Induced Psoriasis-like Skin Inflammation. <i>DNA and Cell Biology</i> , 2021, 40, 1325-1337.	0.9	3
43	Effect of Low-Dose Methotrexate on eGFR and Kidney Adverse Events: A Randomized Clinical Trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 3197-3207.	3.0	11
44	Treatment of Rheumatoid Arthritis by Serum Albumin Nanoparticles Coated with Mannose to Target Neutrophils. <i>ACS Applied Materials &amp; Interfaces</i> , 2021, 13, 266-276.	4.0	39
45	Vaccine considerations for adult dermatology patients on immunosuppressive and immunomodulatory therapies: a clinical review. <i>Dermatology Online Journal</i> , 2021, 27, .	0.2	4
46	Methotrexat: eine randomisierte Studie zur Verträglichkeit. <i>Pharma-Kritik (discontinued)</i> , 2020, 42, .	0.0	0
47	Cardiotoxic effects induced by the use of antimetabolites in the chemotherapy of oncological diseases. <i>Cardiosomatics</i> , 2021, 12, 177-181.	0.2	0
48	Mesenchymal Stem Cell-Based Therapy for Rheumatoid Arthritis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11592.	1.8	36
49	ATIC as a link between antirheumatic drugs and regulation of energy metabolism in skeletal muscle. <i>Periodicum Biologorum</i> , 2020, 121-122, 129-145.	0.1	0
50	Methotrexate Use for Patients with Psoriasis and Risk of Cutaneous Squamous Cell Carcinoma: A Nested Case-control Study. <i>Acta Dermato-Venereologica</i> , 2021, 101, adv00365.	0.6	5
51	Adverse effects related to methotrexate polyglutamate levels: adjudicated results from the cardiovascular inflammation reduction trial. <i>Rheumatology</i> , 2021, 60, 2963-2968.	0.9	3
52	Methotrexate and The Lung in Rheumatoid Arthritis. <i>European Medical Journal Rheumatology</i> , 0, , 80-90.	0.0	1
53	Inhibition of NETosis for treatment purposes: friend or foe?. <i>Molecular and Cellular Biochemistry</i> , 2022, 477, 673-688.	1.4	38
54	Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. <i>New England Journal of Medicine</i> , 2022, 386, 316-326.	13.9	640
55	The safety of antirheumatic drugs. <i>Deutsches A&amp;#x0308;rztblatt International</i> , 0, , .	0.6	7
56	Assessment on Treatments With Conventional Synthetic Disease-modifying Drugs Before Initiating Biologics in Patients With Rheumatoid Arthritis in Korea: A Population-based Study. <i>Journal of Rheumatic Diseases</i> , 2022, 29, 79-88.	0.4	2
58	Comparison of Anticancer Drug Toxicities: Paradigm Shift in Adverse Effect Profile. <i>Life</i> , 2022, 12, 48.	1.1	49
59	Protective Effect of Pycnogenol against Methotrexate-Induced Hepatic, Renal, and Cardiac Toxicity: An In Vivo Study. <i>Pharmaceuticals</i> , 2022, 15, 674.	1.7	7

#	ARTICLE	IF	CITATIONS
61	Genetics are not likely to offer clinically useful predictions for elevated liver enzyme levels in patients using low dose methotrexate. <i>Seminars in Arthritis and Rheumatism</i> , 2022, 55, 152036.	1.6	1
62	A Retrospective Database Cohort Study Evaluating the Association Between Immune Suppressive Therapy and the Development of Cancer in Patients with Atopic Dermatitis Within UK Primary Care. <i>European Medical Journal (Chelmsford, England)</i> , 0, , .	3.0	0
63	Improving COVID-19 vaccine immunogenicity by interrupting methotrexate treatment. <i>Lancet Respiratory Medicine</i> , 2022, 10, 813-815.	5.2	2
64	Myelodysplastic syndrome and autoimmune disorders: two sides of the same coin?. <i>Lancet Haematology</i> , 2022, 9, e523-e534.	2.2	14
65	Methotrexate in interstitial lung disease associated with rheumatoid arthritis. <i>ReumatologĀa ClĀnica (English Edition)</i> , 2022, , .	0.2	0
66	Intervention with methotrexate in patients with arthralgia at risk of rheumatoid arthritis to reduce the development of persistent arthritis and its disease burden (TREAT EARLIER): a randomised, double-blind, placebo-controlled, proof-of-concept trial. <i>Lancet, The</i> , 2022, 400, 283-294.	6.3	56
67	Safety Profile of Methotrexate Therapy in Patients With Rheumatoid Arthritis. <i>Cureus</i> , 2022, , .	0.2	2
68	Methotrexate plus reduced or full-dose glucocorticoids for the treatment of active, moderate-to-severe Graves' orbitopathy. <i>European Thyroid Journal</i> , 2022, , .	1.2	1
69	Management of progressive pulmonary fibrosis associated with connective tissue disease. <i>Expert Review of Respiratory Medicine</i> , 2022, 16, 765-774.	1.0	6
70	A highly selective JAK3 inhibitor is developed for treating rheumatoid arthritis by suppressing ĩc cytokineĀ-related JAK-STAT signal. <i>Science Advances</i> , 2022, 8, .	4.7	19
71	SER-SEPAR recommendations for the management of rheumatoid arthritis-related interstitial lung disease. Part 2: Treatment. <i>ReumatologĀa ClĀnica (English Edition)</i> , 2022, 18, 501-512.	0.2	3
72	Ulcerative colitis-associated bronchiectasis: A rare extraintestinal manifestation of inflammatory bowel disease: A case report. <i>Medicine (United States)</i> , 2022, 101, e30202.	0.4	0
73	Development of Methotrexate Complexes Endowed with New Biological Properties Envisioned for Musculoskeletal Regeneration in Rheumatoid Arthritis Environments. <i>International Journal of Molecular Sciences</i> , 2022, 23, 10054.	1.8	1
74	Overview of Methotrexate Toxicity: A Comprehensive Literature Review. <i>Cureus</i> , 2022, , .	0.2	24
75	Calcium-Permeable Channels Cooperation for Rheumatoid Arthritis: Therapeutic Opportunities. <i>Biomolecules</i> , 2022, 12, 1383.	1.8	4
76	Pooled Analysis of Meningioma Risk Following Treatment for Childhood Cancer. <i>JAMA Oncology</i> , 2022, 8, 1756.	3.4	9
77	Integrated Microbiome and Metabolome Analysis Reveals Correlations Between Gut Microbiota Components and Metabolic Profiles in Mice with Methotrexate-Induced Hepatotoxicity. <i>Drug Design, Development and Therapy</i> , 0, Volume 16, 3877-3891.	2.0	9
78	Busting the myth of methotrexate chronic hepatotoxicity. <i>Nature Reviews Rheumatology</i> , 2023, 19, 96-110.	3.5	11

#	ARTICLE	IF	CITATIONS
79	Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, 331-343.	0.5	48
81	Protective Effects of <i>Momordica charantia</i> (Bitter Melon) against Methotrexate-induced Kidney Damage. <i>Current Drug Therapy</i> , 2023, 18, .	0.2	0
82	Synthetic Pharmacotherapy for Systemic Lupus Erythematosus: Potential Mechanisms of Action, Efficacy, and Safety. <i>Medicina (Lithuania)</i> , 2023, 59, 56.	0.8	3
84	<i>Tripterygium wilfordii</i> Hook F combination therapy with methotrexate for rheumatoid arthritis: An updated meta-analysis. <i>Journal of Ethnopharmacology</i> , 2023, 307, 116211.	2.0	3
85	Methotrexate-induced liver fibrosis: The end of a long-held belief. <i>Journal of Hepatology</i> , 2023, 78, 896-897.	1.8	3
86	Editorial: Disease-modifying antirheumatic drugs: Approaches and lessons learned from traditional medicine. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	1
87	Use of methotrexate and risk of skin cancer: a nationwide caseâ€“control study. <i>British Journal of Cancer</i> , 2023, 128, 1311-1319.	2.9	7
89	Frequency of <i>Helicobacter pylori</i> in Patients With Rheumatoid Arthritis Whose Methotrexate Was Stopped Due to Gastrointestinal Intolerance. <i>Journal of Clinical Rheumatology</i> , 0, Publish Ahead of Print, .	0.5	0
90	In silico screening of inhibitors against human dihydrofolate reductase to identify potential anticancer compounds. <i>Journal of Biomolecular Structure and Dynamics</i> , 0, , 1-13.	2.0	0
91	Pacientes con enfermedad injerto contra huÃ©sped e infecciones asociadas al rechazo de trasplante. <i>Ciencia Y Salud</i> , 2023, 7, 55-63.	0.1	0
92	Dihydromyricetin Modulates Nrf2 and NF-Î²B Crosstalk to Alleviate Methotrexate-Induced Lung Toxicity. <i>Pharmaceuticals</i> , 2023, 16, 481.	1.7	1
93	Use of Systemic Therapies for Treatment of Psoriasis in Patients with a History of Treated Solid Tumours: Inference-Based Guidance from a Multidisciplinary Expert Panel. <i>Dermatology and Therapy</i> , 2023, 13, 867-889.	1.4	2
94	Adverse events during short- and long-term exposure to low-dose weekly methotrexate for rheumatic diseases. <i>Rheumatology Advances in Practice</i> , 0, , .	0.3	0